Drugs / WT1-CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02895412 | Aug 2016 → Dec 2020 | acute myeloid leukemia | University of Sydney | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2015-12-05 | Atara Biotherapeutics | Results Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies atarabio.com ↗
By one year, 3 achieved a complete remission (CR), 1 achieved a partial response (PR), 2 had stable disease (SD), and 1 had progressive disease. |
| 2015-09-24 | Atara Biotherapeutics | Results Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia atarabio.com ↗
By one year, of seven subjects with relapsed-refractory MM or PCL receiving an alloHCT and treated with WT1-CTLs, three achieved a complete remission (CR), one achieved a partial response (PR), two had stable disease (SD) and one had progressive disease. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-12-05 | Atara Biotherapeutics | Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies atarabio.com ↗ |
| 2015-09-24 | Atara Biotherapeutics | Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia atarabio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02895412 ↗ |
| Modality | Cell therapy | “donor-derived Wilm's Tumour Antigen-specific cytotoxic T lymphocytes” NCT02895412 ↗ |
| Route | Other | “monthly infusions of WT1-CTL for up to four doses” NCT02895412 ↗ |